Therapeutic Targets for Heart Failure Identified Using Proteomics and Mendelian Randomization
Year: 2022
Type: review
Study design: Observational Study
Abstract: Background: Heart failure (HF) is a highly prevalent disorder for which disease mechanisms are incompletely understood. The discovery of disease-associated proteins with causal genetic evidence provides an opportunity to identify new therapeutic targets. Methods: We investigated the observational and causal associations of 90 cardiovascular proteins, which were measured using affinity-based proteomic assays. First, we estimated the associations of 90 cardiovascular proteins with incident heart failure by means of a fixed-effect meta-analysis of 4 population-based studies, composed of a total of 3019 participants with 732 HF events. The causal effects of HF-associated proteins were then investigated by Mendelian randomization, using cis -protein quantitative loci genetic instruments identified from genomewide association studies in more than 30 000 individuals. To improve the precision of causal estimates, we implemented an Mendelian randomization model that accounted for linkage disequilibrium between instruments and tested the robustness of causal estimates through a multiverse sensitivity analysis that included up to 120 combinations of instrument selection parameters and Mendelian randomization models per protein. The druggability of candidate proteins was surveyed, and mechanism of action and potential on-target side effects were explored with cross-trait Mendelian randomization analysis. Results: Forty-four of ninety proteins were positively associated with risk of incident HF ( P <6.0×10 –4 ). Among these, 8 proteins had evidence of a causal association with HF that was robust to multiverse sensitivity analysis: higher CSF-1 (macrophage colony-stimulating factor 1), Gal-3 (galectin-3) and KIM-1 (kidney injury molecule 1) were positively associated with risk of HF, whereas higher ADM (adrenomedullin), CHI3L1 (chitinase-3-like protein 1), CTSL1 (cathepsin L1), FGF-23 (fibroblast growth factor 23), and MMP-12 (matrix metalloproteinase-12) were protective. Therapeutics targeting ADM and Gal-3 are currently under evaluation in clinical trials, and all the remaining proteins were considered druggable, except KIM-1. Conclusions: We identified 44 circulating proteins that were associated with incident HF, of which 8 showed evidence of a causal relationship and 7 were druggable, including adrenomedullin, which represents a particularly promising drug target. Our approach demonstrates a tractable roadmap for the triangulation of population genomic and proteomic data for the prioritization of therapeutic targets for complex human diseases.
Source: Circulation
Authors: Albert Henry, María Gordillo-Marañón, Chris Finan, Amand F. Schmidt, João Pedro Ferreira, Ravi Karra, Johan Sundström, Lars Lind, Johan Ärnlöv, Faiez Zannad, Anders Mälarstig, Aroon D. Hingorani, R. Thomas Lumbers, HERMES and SCALLOP Consortia
Institutions: British Heart Foundation, University College London, University Medical Center Utrecht, Inserm, Universidade do Porto, French Clinical Research Infrastructure Network, Défaillance Cardiovasculaire Aiguë et Chronique, Unidade de Investigação e Desenvolvimento Cardiovascular, Université de Lorraine, Duke University, Duke Medical Center, Uppsala University, UNSW Sydney, The George Institute for Global Health, Dalarna University, Karolinska Institutet, Pfizer (United States), Health Data Research UK
Language: English
Subfield: Genetics
Domain: Life Sciences
Open Access status: hybrid
Funders: UK Research and Innovation, National Institute for Health and Care Research, British Heart Foundation, University College London, Rosetrees Trust, Hjärt-Lungfonden, Vetenskapsrådet, National Institutes of Health, Medical Research Council, National Heart, Lung, and Blood Institute, U.S. National Library of Medicine
Awards: G160220429, UCL 2nd intake 2018 4-Year PhD Studentship (4th) Scheme: Ms Vanessa Acquaah; Mr Albert Henry; Ms Victoria Rashbrook; Mr Benjamin Ringham-Terry (4 years), G3217537052, G3259981160, UCL 1st intake 2017 4 Year PhD Studentship (4th) Scheme: Ms Annalisa Bettini; Ms Jasmine Gratton; Ms Maria Maranon; Mr Michael Magnussen (4 years), Accelerator Award (round 1), 'Unlocking therapeutic innovation in heart failure through genomic data science, G5005581103, Angiogenic Approaches to Stimulate Heart Regeneration, Bioinformatics Strategies for Genome Wide Association Studies, Evaluating combination therapeutics for CVD prevention using Mendelian randomization and phenome-wide scans, G6814491137, NIHR Senior Investigator Award
OpenAlex ID: W4220714531
